Actively Recruiting
Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement
Led by Shaklee Corporation · Updated on 2026-04-13
34
Participants Needed
1
Research Sites
14 weeks
Total Duration
On this page
Sponsors
S
Shaklee Corporation
Lead Sponsor
B
Biofortis Clinical Research, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.
CONDITIONS
Official Title
Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females aged 45 to 65 years
- Body mass index (BMI) between 18.5 and less than 30.0 kg/m2
- Able to walk and free of injuries or impairments that limit mobility
- Willing to use a personal smartphone with Android version 12.0 or newer, or iOS version 16 or newer
- Willing to maintain current skin care routine and avoid skin-related medical procedures
- Willing to follow all study procedures and provide informed consent
You will not qualify if you...
- Currently following or planning a weight loss regimen
- Recent weight loss or gain greater than 4.5 kg
- History of gastrointestinal surgery for weight loss
- History of eating disorders such as anorexia nervosa, bulimia nervosa, or binge eating
- History of neurological disorders that cause cognitive decline
- History of delirium, confusion, or head injury
- History of unusual sleep patterns or diagnosed sleep disorders
- History of infectious or inflammatory brain diseases
- Use of tobacco or nicotine products
- Use of hemp or marijuana products
- Unstable use of prescription medications
- Unstable use or recent changes in hormonal contraceptives or therapy
- Use of dietary supplements other than a once-daily multivitamin
- Use of medications or supplements affecting absorption
- Recent or potential alcohol or substance abuse
- Exposure to any non-registered drug products
- Vein access assessment score less than 7
- History or presence of significant cardiac, kidney, liver, endocrine, lung, gastrointestinal, biliary, pancreatic, or neurological diseases
- Uncontrolled high blood pressure
- Known allergies to study product ingredients
- Signs or symptoms of active infections
- History or presence of cancer within past 2 years, except non-melanoma skin cancer
- History of major trauma or surgery
- Females who are pregnant, planning pregnancy, breastfeeding, or with unstable contraception
- Employees or representatives with financial interest in the sponsor organization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Biofortis Clinical Research
Addison, Illinois, United States, 60101
Actively Recruiting
Research Team
B
Biofortis Research Clinical Director Biofortis Research Clinical Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here